The Evolution of Fluorescein into A Potential Theranostic Tool

Recent advances in drug discovery and development have been marked by the emergence of new modalities, including small molecule theranostic agents. While initial results from clinical trials have been promising, modern detectable inhibitors are still in an early stage of development. In this study, we present a strategy for chemically evolving a fluorescent imaging agent into a potent therapeutic entity, which not only retains its properties but also enhances its inhibition and detection applicability. By utilizing 15-LOX-1 as a model system, we leverage prior knowledge of its inhibitors to rationally functionalize fluorescein, enabling the targeted and highly efficient synthesis of over 20 derivatives across four different scaffolds. This approach ultimately led to the development of a potent, cell-permeable inhibitor that effectively engages its target in live cells and enables real-time visualization. These findings validate our new strategy for the development of small molecule diagnostic modulators, paving the way for application in other targets as well.

Authors

Institutions

Publication Details

Journal
Chemistry - A European Journal
Published
2025-05-02
DOI
https://doi.org/10.1002/chem.202501513
Citations
3
Primary Topic
14-3-3 protein interactions
Type
article
Field-Weighted Citation Impact
2.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Evolution of Fluorescein into A Potential Theranostic Tool

Christos Papadopoulos, Constantinos G. Neochoritis, Konstantinos S. Adamis, Dimitris Korovesis et al.
3 citations
Chemistry - A European Journal
14-3-3 protein interactions
2.42
article

The Evolution of Fluorescein into A Potential Theranostic Tool

Christos Papadopoulos, Constantinos G. Neochoritis, Konstantinos S. Adamis, Dimitris Korovesis, Nektarios Tavernarakis, Nikolaos Eleftheriadis, Michail Georgoulakis, Ioannis Angelonidis, Michael Kapsalis
article en
3 citations

Abstract

Recent advances in drug discovery and development have been marked by the emergence of new modalities, including small molecule theranostic agents. While initial results from clinical trials have been promising, modern detectable inhibitors are still in an early stage of development. In this study, we present a strategy for chemically evolving a fluorescent imaging agent into a potent therapeutic entity, which not only retains its properties but also enhances its inhibition and detection applicability. By utilizing 15-LOX-1 as a model system, we leverage prior knowledge of its inhibitors to rationally functionalize fluorescein, enabling the targeted and highly efficient synthesis of over 20 derivatives across four different scaffolds. This approach ultimately led to the development of a potent, cell-permeable inhibitor that effectively engages its target in live cells and enables real-time visualization. These findings validate our new strategy for the development of small molecule diagnostic modulators, paving the way for application in other targets as well.

Chemistry - A European JournalVol. 31(34)
University of Crete (GR), FORTH Institute of Molecular Biology and Biotechnology (GR), Foundation for Research and Technology Hellas (GR)
Good health and well-being
Openalex Percentile: Top 12%
14-3-3 protein interactions
2.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.